A Clinical Trial of the STAT3 Inhibitor Pyrimethamine in Chronic Lymphocytic Leukemia.  132:1855-1855. 2018

Ineffective erythropoiesis of TET2 deficiency.  132:2320-2321. 2018

FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML).  128:1681-1681. 2016

Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent..  128:1845-1853. 2016

Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome..  127:948-951. 2016

Emerging EPO and EPO receptor regulators and signal transducers..  125:3536-3541. 2015

The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma..  125:3118-3127. 2015

Erythroid mRNA processing: a "splice of life"..  124:474-475. 2014

Targeting STAT5 in Leukemia Through Inhibition of Bromodomain Proteins.  120:399-399. 2012

Spry1 as a novel regulator of erythropoiesis, EPO/EPOR target, and suppressor of JAK2..  119:5522-5531. 2012

Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity..  118:5540-5549. 2011

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors..  117:3421-3429. 2011

During EPO or anemia challenge, erythroid progenitor cells transit through a selectively expandable proerythroblast pool..  116:5334-5346. 2010

Micro-mismanaging sickle cell stress..  116:4040-4042. 2010

Inhibition of Both Jak2 and STAT5 Enhances Toxicity to Myeloproliferative Cells..  114:1905-1905. 2009

Inhibition of the Jak/Stat Pathway Downregulates Immunoglobulin Production and Induces Cell Death in Waldenström Macroglobulinemia..  114:1691-1691. 2009

Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells..  114:2936-2944. 2009

CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools..  113:4955-4962. 2009

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3..  112:5095-5102. 2008

Comprehensive Analysis of the Waldenström Macroglobulinemia “Cytokine Milieu” Reveals a Novel Role of Rantes Signaling in the Regulation of Immunoglobulin Production.  112:618-618. 2008

Monocytes Promote Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma and Are Recruited to the Tumor Microenvironment by CCL5 (RANTES).  112:378-378. 2008

miRNA Analysis Identifies a Unique Expression in Waldenström Macroglobulinemia B Cells and Plasma Cells.  112:620-620. 2008

Attenuation of EPO-dependent erythroblast formation by death-associated protein kinase-2..  112:886-890. 2008

EPO receptor circuits for primary erythroblast survival..  111:5390-5399. 2008

Multiplex Analysis of Serum Cytokine Levels in Waldenström Macroglobulinemia Patients..  110:2616-2616. 2007

Pimozide Inhibits STAT5 Signaling in Chronic Myelogenous Leukemia and Reduces the Viability of Both Imatinib Sensitive and Imatinib Resistant Cells..  110:2953-2953. 2007

Role of CCL5 and Interleukin-6 in the Biology of Waldenström Macroglobulinemia..  110:688-688. 2007

EPO modulation of cell-cycle regulatory genes, and cell division, in primary bone marrow erythroblasts..  110:2361-2370. 2007

Erythropoietin modulation of podocalyxin and a proposed erythroblast niche..  110:509-518. 2007

Nifuroxazide Inhibits STAT3 Function and Shows Potent Anti-Tumor Activity Against Multiple Myeloma..  108:3450-3450. 2006

Lyn kinase promotes erythroblast expansion and late-stage development..  108:1524-1532. 2006

Selective activation of TACI by syndecan-2..  107:3235-3242. 2006

B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia..  107:2882-2888. 2006

Core erythropoietin receptor signals for late erythroblast development..  107:2662-2672. 2006

Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation..  106:3191-3199. 2005

Attenuated signaling by a phosphotyrosine-null Epo receptor form in primary erythroid progenitor cells..  102:3147-3153. 2003

Erythropoietin receptor-dependent erythroid colony-forming unit development: capacities of Y343 and phosphotyrosine-null receptor forms..  99:898-904. 2002

mDYRK3 kinase is expressed selectively in late erythroid progenitor cells and attenuates colony-forming unit-erythroid development..  97:901-910. 2001

A minimal cytoplasmic subdomain of the erythropoietin receptor mediates erythroid and megakaryocytic cell development..  94:3381-3387. 1999

Erythropoietin receptor and STAT5-specific pathways promote SKT6 cell hemoglobinization..  92:1104-1118. 1998

Tumor Cell Cytotoxicity of a Novel Metal Chelator.  92:1384-1389. 1998

Tumor cell cytotoxicity of a novel metal chelator..  92:1384-1389. 1998

Mechanisms of stem cell factor and erythropoietin proliferative co-signaling in FDC2-ER cells..  90:3533-3545. 1997

Hematopoietic cell phosphatase negatively regulates erythropoietin-induced hemoglobinization in erythroleukemic SKT6 cells..  90:2175-2187. 1997

Functional interaction of GATA1 with erythroid Krüppel-like factor and Sp1 at defined erythroid promoters..  87:1793-1801. 1996

Signal transduction by the receptors for thrombopoietin (c-mpL) and interleukin-3 in hematopoietic and nonhematopoietic cells..  86:557-571. 1995

Steel factor affects SCL expression during normal erythroid differentiation..  84:2971-2976. 1994

Association of the p85 regulatory subunit of phosphatidylinositol 3-kinase with an essential erythropoietin receptor subdomain..  82:3530-3538. 1993

BIOTINYLATED ERYTHROPOIETIN - REPLY.  74:2772-2773. 1989

Biotinylated recombinant human erythropoietins: bioactivity and utility as receptor ligand..  74:952-958. 1989

High-level expression and purification of a recombinant human erythropoietin produced using a baculovirus vector..  74:652-657. 1989

Novel EPO/EPOR/JAK2 targets and signal transduction pathways revealed by phospho-PTM proteomic profiling

"RHEX" / C1ORF186 Governs JAK2 Activation, Differentially Modulates STAT-5 and-3, Balances Human Erythroblast Development, and Becomes Essential during Red Cell Formation 2020

"C1ORF150", a Novel Mediator of EPO/EPOR/JAK2 Dependent Human Erythroid Progenitor Cell Formation 2016

EPO Modulation of Thioredoxin Interacting Protein (TXNIP), and Key Roles for TXNIP during EPO-Dependent Human Erythroid Progenitor Cell Growth and Development 2015

Podocalyxin Negatively Regulates Stress Myelopoiesis, Directly Binds Rap-1A and Modulates Its G-CSF-Induced Activity 2015

A Novel Mechanism of GLI2 Mediated Regulation of IgM Secretion in Waldenstrom Macroglobulinemia 2014

Discovery of Novel EPO/EPOR/JAK2 Targets and Signal Transduction Factors Via Proteomic-Based Interrogations of Post-Translational Motif Modifications 2014

GLI Transcription Factors Modulate IgM Secretion In Waldenstrom Macroglobulinemia 2013

GLI2 Transcription Factor Modulates CD40 Ligand Expression In Bone Marrow Stromal Cells 2013

Ligand-Regulated and Developmental Stage-Specific Expression Of The EPO Receptor During Human Erythroid Progenitor Cell Formation 2013

The Transcription Factor GLI3 Is a Novel Candidate Effector Of Toll-Like Receptor 4 (TLR4) Signaling In Monocytes 2013

Trib2 Pseudokinase Marks Early CMP Progenitors, and Promotes Granulocytic Plus Erythroid Progenitor Cell Formation 2013

Erythropoietin-Directed Erythropoiesis Depends Upon Serpin Inhibition of Erythroblast Lysosomal Cathepsins 2012

Hematopoietic Lineage Selective Roles for Trib Pseudokinases Post Bone Marrow Transplantation 2012

The Erythropoiesis Stimulating Agent Omontys/Peginesatide up-Modulates Erythroid Progenitor Formation, and Cell Surface Erythropoietin Receptor Levels 2012

"RHEX-26", a Novel EPO/EPOR-Regulated Mediator of Human Erythroid Progenitor Cell Expansion 2011

Dynamic Erythropoietin Receptor Trafficking Within Cell Surface, and Intracellular Pools 2010

Epo Engages a Tnfr-13c Pathway to Advance for Primary Bone Marrow (Pro)Erythroblast Development 2010

GLI2, An Effector of the Hedgehog Pathway, Is a Novel Regulator of IL6 Oncogenic Function In the Tumor Microenvironment 2010

GLI2, An Effector of the Hedgehog Pathway, Is a Novel Regulator of IL6 Oncogenic Function In the Tumor Microenvironment 2010

BMP Signaling Is Crucial for Regulation Vascular Progenitor Development in Human Embryonic Stem Cells. 2009

Inhibition of the Jak/Stat Pathway Downregulates Immunoglobulin Production and Induces Cell Death in Waldenstrom Macroglobulinemia. 2009

Spry1 Plays Selective Hematopoietic Roles as An Erythropoietin - Modulated Positive Regulator of Erythropoiesis 2009

TRIB3 Pseudokinase Is Induced Via An EPO/EPOR/STAT5 Pathway, Markedly up-Modulated in Late-Stage Erythroblasts, and Plays An Essential Non-Redundant Role During Stress Erythropoiesis 2009

Comprehensive Analysis of the Waldenstrom Macroglobulinemia "Cytokine Milieu" Reveals a Novel Role of Rantes Signaling in the Regulation of Immunoglobulin Production 2008

Monocytes Promote Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma and Are Recruited to the Tumor Microenvironment by CCL5 2008

Non-Redundant Roles for an Epo/EpoR/STAT5 Regulated Intracellular Serpin, Serpina-3G, during Epo- and Anemia- Induced Erythropoiesis 2008

miRNA Analysis Identifies a Unique Expression in Waldenstrom Macroglobulinemia B Cells and Plasma Cells 2008

GSK626616: A DYRK3 inhibitor as a potential new therapy for the treatment of anemia 2007

Multiplex analysis of serum cytokine levels in Waldenstrom macroglobulinemia patients 2007

Epo modulation of cell cycle regulatory genes via PY343/STAT5 and PI3K pathways in primary erythroblasts. 2006

Epo receptor circuits to Irs2, Foxo3a, Trb3 and Bim 1 expression, and erythroblast survival. 2006

Erythropoietin modulation of podocalyxin within an erythroblast niche. 2006

Preferential inhibition of malignant cell growth by CDDO in Waldenstrom macroglobulinemia. 2006

Transgenic GATA1ie3.9int - DAPK2 mice exhibit low-grade anemia, deficient stress erythropoiesis, and compromised erythroblast survival. 2006

Role of B-lymphocyte stimulator (BLyS) in Waldenstrom's macroglobulinemia. 2005

Core epo receptor signaling circuits in adult bone marrow-derived primary pro-erythroblasts. 2004

Death associated protein kinase 2 (DAPK2): A novel Epo-modulated apoptotic regulator of late erythropoiesis. 2004

Kit PY567-directed signals are important for efficient erythroid progenitor cell proliferation and survival, and are attenuated by Kit PY569. 2004

Lyn kinase supports primary erythroid progenitor cell development. 2004

Assisting mechanisms during PY-null Epo receptor allele dependent steady-state erythropoiesis. 2003

Stress erythropoiesis is not efficiently supported by a minimal Epo receptor phosphotyrosine-null allele. 2003

DYRK3 activation mechanisms, PKA/CREB engagement and modulation of progenitor cell survival. 2002

Dynamics of pro-erythroblasts growth and differentiation revealed through gene profiling. 2002

Roles for Epo receptor Y343 (and Stat5) in Kit synergy. 2002

Purification of developmentally staged erythroid progenitor cells in numbers sufficient for gene profiling of CFUe development. 2001

SCF/Epo synergy in primary CFUe is mediated efficiently by Epo receptor phosphotyrosine-independent mechanisms. 2001

An optimized primary cell system for investigators of regulated erythropoiesis: Developmentally synchronized splenic erythroid progenitor cells from thiamphenicol-treated transgenic mice. 2000

Erythroid-restricted expression and repressive role for mDYRK3 dual-specificity kinase in CFUe development. 2000

Critical, concentrations of FOG are required for alpha IIb gene activation via both GATA-1-dependent, and independent mechanisms. 1999

SCF synergizes with Epo via Epo receptor (p)y-dependent and -independent routes, selectively enhances Epo/Jak2/STAT5-dependent bclx & bcl2 gene transcription, and is the primary activator of Erks. 1999

Regulation of GATA-1 gene expression: Roles for FOG, GATA-1, EPO, and novel activating and repressing cis-domains. 1998

Subtraction cloning and initial characterization of novel EPO-response genes. 1998

Co-expression of GATA-1 and the Epo receptor in myeloid FDCW2 cells prolongs the cell cycle at G(1), attenuates proliferation and activates endogenous erythroid gene expression. 1997

Pim1 inhibits cell death: Induction of Pim1 and Pim2 transcription via a minimal Epo receptor form and modulation of apoptosis upon the deregulated expression of Pim1. 1997

Epo-induced hemoglobinization of SKT6 cells is blocked by a dominant-negative form of STAT5. 1996

EPO signaling via minimal mitogenic receptor forms, and via STAT factors in differentiating erythroid SKT6-40 cells. 1995

ROLES FOR JAK2 KINASE IN EPO-INDUCED MITOGENESIS, INHIBITED APOPTOSIS, AND ERYTHROID-DIFFERENTIATION 1994

ASSOCIATION OF P85/P13-K WITH THE EPO RECEPTOR WITHIN THE EXTENDED BOX-2 DOMAIN, AND POSSIBLE ROLES FOR JAK-2 IN P13-K ACTIVATION 1993

Immunology